By Josh White
Date: Tuesday 09 Dec 2025
(Sharecast News) - Sareum updated investors on progress across its pipeline ahead of its annual general meeting on Tuesday, highlighting continued advances in its lead autoimmune candidate SDC-1801 and strengthening commercial positioning for its cancer assets SDC-1802 and SRA737.
By Iain Gilbert
Date: Friday 10 Oct 2025
(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
By Josh White
Date: Thursday 29 May 2025
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
| Currency | UK Pounds |
| Share Price | 20.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 21.00 |
| 52 Week Low | 19.84 |
| Volume | 31,567 |
| Shares Issued | 138.57m |
| Market Cap | £27.71m |
| RiskGrade | 594 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:00 | 529 @ 19.85p |
| 13:30 | 7,557 @ 19.85p |
| 10:36 | 110 @ 21.00p |
| 10:36 | 2,556 @ 19.84p |
| 09:09 | 15,765 @ 19.84p |
You are here: research